Post-Effective Date Affiliates. In the event that RBNC or its Affiliates or Sublicensees enters into a Distracting Transaction with a Third Party (and for clarity, RBNC has not elected to treat such Distracting Product as a Newly Added Product pursuant to Section 5.4.2), then RBNC shall provide prompt written notice to AMGEN. Until the provisions of Section 5.4.4 (Termination or Divestiture) are effectuated, RBNC (or its Sublicensee) shall ensure that information and materials relating to the Products or activities hereunder are not shared with or used for the benefit of, and are sequestered from, Distracting Transaction Affiliate(s).
Appears in 4 contracts
Samples: Exclusive License Agreement for Gcase (Neumora Therapeutics, Inc.), Exclusive License Agreement for Ck1d (Neumora Therapeutics, Inc.), Exclusive License Agreement for Ck1d (Neumora Therapeutics, Inc.)
